YFYves Fromes

Yves Fromes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yves Fromes has a total of 306 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Whole-Body Muscle MRI in Non-5q Spinal Muscular Atrophy

    by Edouard Berling, Harmen Reyngoudt, Adrien Le Guillou, Jean-Baptiste Noury, Pascal Cintas, Bruno Cadot, Isabelle Ackermann-Bonan, Benjamin Marty, Yves Fromes, Gorka Fernandez-Eulate, et al.

    Background and ObjectivesSpinal muscular atrophy (SMA) is a group of genetically heterogeneous motor neuron disorders characterized by progressive, predominantly proximal weakness. Non-5q SMA refer...


  • Open Access

    Multi-parametric quantitative MRI of the lower limb muscles in a longitudinal study of limb-girdle muscular dystrophy R9

    by Susanne S. Rauh, Pierre-Yves Baudin, Tanya Stojkovic, Simone Birnbaum, Valérie Decostre, Rachida-Lydie Zanfongnon, Yves Fromes, Melissa T. Hooijmans, Gustav J. Strijkers, Jean-Yves Hogrel, et al.

    Background and Objectives: Limb-girdle muscular dystrophy R9 (LGMD-R9) is a rare neuromuscular disease with no curative treatment. Sensitive non-invasive biomarkers are necessary to monitor disease progression and evaluate the efficacy of novel therapies. Here, we investigated several quantitative MRI parameters as suitable biomarkers for evaluating disease progression in LGMD-R9. Methods: Bilateral quantitative MRI of the lower limbs was performed in individuals with LGMD-R9 and healthy controls. Quantitative thigh and leg muscle MRI, functional tests (including time-up-and-go (TUG) and time-to-climb-4-stairs (4S climb)), and muscle strength tests were performed in individuals with LGMD-R9 at baseline, 1-year, and 2-years. qMRI included assessment of muscle fat fraction (FF), water T2, water T1, intramuscular pH from 1H MR spectroscopy, and diffusion tensor imaging (DTI) parameters. Differences between LGMD-R9 and controls, over time, and the relationship between baseline water T1 and water T2 parameters and disease progression (FF, functional and strength parameters) were assessed by linear mixed models and correlation analyses. Results: 18 individuals with LGMD-R9 and 13 controls were enrolled. At baseline, elevated FF, water T2, water T1, and pH were observed in LGMD-R9 (p < 0.05). No differences between controls and LGMD-R9 were found in the DTI parameters. An overall tendency to an increase in FF and a decrease in functional measures were observed over 2 years. However, the changes did not reach significance (p = 0.057–0.752). Baseline water T1 and baseline water T2 correlated with the increase in FF (ΔFF) and change in TUG (ΔTUG) and 4S climb (Δ4S climb) over 2 years (correlation coefficient ≥ 0.6, p < 0.05). No correlation with the strength measures was found. Conclusion: Our findings suggest that FF, water T2, water T1, and pH are effective biomarkers for LGMD-R9. The correlation of water T2 and water T1 with ΔFF, ΔTUG, and Δ4S climb suggests their potential in predicting disease progression.


  • Open Access

    Reduced microvascular flow-mediated dilation in Syrian hamsters lacking δ-sarcoglycan is caused by increased oxidative stress

    by Alexis Richard, Arnaud Bocquet, Eric Belin de Chantemèle, Kevin Retailleau, Bertrand Toutain, Héloïse Mongue-Din, Anne-Laure Guihot, Céline Fassot, Yves Fromes, Daniel Henrion, et al.

    This study suggests that the sarcoglycan complex is selectively involved in flow-mediated dilation, thus highlighting its role in endothelial responsiveness to shear stress and amplifying tissue damage in myopathy.


  • Multiparametric Aging Study Across Adulthood in the Leg Through Quantitative MR Imaging, 1H Spectroscopy, and 31P Spectroscopy at 3T

    by Alfredo L. Lopez Kolkovsky, Beatrice Matot, Pierre‐Yves Baudin, Ericky Caldas de Almeida Araujo, Harmen Reyngoudt, Benjamin Marty, Yves Fromes

    Background: Improved characterization of healthy muscle aging is needed to establish early biomarkers in age‐related diseases.Purpose: To quantify age‐related changes on multiple MRI and clinical variables evaluated in the same cohort and identify correlations among them.Study Type: Prospective.Population: 70 healthy subjects (30 men) from 20 to 81 years old.Field Strength/Sequence: 3T/water T2 (multiecho SE, multi‐TE STEAM), water T1 (GRE MR Fingerprinting), fat‐fraction (multiecho GRE, multi‐TE STEAM), carnosine (PRESS), multicomponent water T2 (ISIS‐CPMG SE train), and 31P pulse‐acquire spectroscopy.Assessment: Age‐ and sex‐related changes on: Imaging: fat‐fraction (FFMRI), water T1 (T1‐H2O), and T2 (T2‐H2O‐MRI) and their heterogeneities ΔT1‐H2O and ΔT2‐H2O‐MRI in the posterior compartment (PC) and anterior compartment (AC) of the leg. 1H spectroscopy: Carnosine concentration, pH, water T2 components (T2‐H2O‐CPMG), fat‐fraction (FFMRS), and water T2 (T2‐H2O‐MRS) in the gastrocnemius medialis. 31P spectroscopy: Phosphodiesters (PDE), phosphomonoesters, inorganic phosphates (Pi), and phosphocreatine (PCr) normalized to adenosine triphosphate (ATP) and pH in the calf. Clinical evaluation: Body‐mass index (BMI), gait speed (GS), plantar flexion strength, handgrip strength (HS), HS normalized to wrist circumference (HSnorm), physical activity assessment. Statistical Tests: Multilinear regressions with sex and age as fixed factors. Spearman correlations calculated between variables. Benjamini–Hochberg procedure for false positives reduction (5% rate). A P < 0.05 significance level was used.Results: Significant age‐related increases were found for BMI (ρAge = 0.04), HSnorm (ρAge = −0.01), PDE/ATP (ρAge = 2.8 × 10−3), Pi/ATP (ρAge = 2.0 × 10−3), Pi/PCr (ρAge = 0.3 × 10−3), T2‐H2O‐MRS (ρAge = 0.051 msec), FFMRS (ρAge = 0.036) the intermediate T2‐H2O‐CPMG component time (ρAge = 0.112 msec), and fraction (ρAge = −0.3 × 10−3); and in both compartments for FFMRI (ρAge = 0.06, PC; ρAge = 0.06, AC), T2‐H2O‐MRI (ρAge = 0.05, PC; ρAge = 0.05, AC; msec), ΔT2‐H2O‐MRI (ρAge = 0.02, PC; ρAge = 0.02, AC; msec), T1‐H2O (ρAge = 1.08, PC; ρAge = 1.06, AC; msec), and ΔT1‐H2O (ρAge = 0.22, PC; ρAge = 0.37, AC; msec). The best age predictors, accounting for sex‐related differences, were HSnorm (R2 = 0.52) and PDE/ATP (R2 = 0.44). In both leg compartments, the imaging measures and HSnorm were intercorrelated. In PC, T2‐H2O‐MRS and FFMRS also showed numerous correlations to the imaging measures. PDE/ATP correlated to T1‐H2O, T2‐H2O‐MRI, ΔT2‐H2O‐MRI, FFMRI, FFMRS, the intermediate T2‐H2O‐CPMG, BMI, Pi/PCr, and HSnorm.Data Conclusion: Our multiparametric MRI approach provided an integrative view of age‐related changes in the leg and revealed multiple correlations between these parameters and the normalized HS.Level of Evidence: 1Technical Efficacy: Stage 3


  • Assessment of Extracellular Volume Fraction in Becker Muscular Dystrophy by Using MR Fingerprinting

    by Benjamin Marty, Pierre-Yves Baudin, Ericky Caldas de Almeida Araujo, Yves Fromes, Karim Wahbi, Harmen Reyngoudt

    Background Quantitative MRI is increasingly proposed in clinical trials related to dystrophinopathies, including Becker muscular dystrophy (BMD). Purpose To establish the sensitivity of extracellular volume fraction (ECV) quantification using an MR fingerprinting sequence with water and fat separation as a quantitative imaging biomarker of skeletal muscle tissue alterations in BMD compared with fat fraction (FF) and water relaxation time quantification. Materials and Methods In this prospective study, study participants with BMD and healthy volunteers were included from April 2018 until October 2022 (ClinicalTrials.gov identifier NCT02020954). The MRI examination comprised FF mapping with the three-point Dixon method, water T2 mapping, and water T1 mapping before and after an intravenous injection of a gadolinium-based contrast agent by using MR fingerprinting, from which ECV was calculated. Functional status was measured with use of the Walton and Gardner-Medwin scale. This clinical evaluation tool stratifies disease severity from grade 0 (preclinical; elevated creatine phosphokinase; all activities normal) to grade 9 (unable to eat, drink, or sit without assistance). Mann-Whitney U tests, Kruskal-Wallis tests, and Spearman rank correlation tests were performed. Results Twenty-eight participants with BMD (median age, 42 years [IQR, 34-52 years]; 28 male) and 19 healthy volunteers (median age, 39 years [IQR, 33-55 years]; 19 male) were evaluated. ECV was higher in participants with dystrophy than in controls (median, 0.21 [IQR, 0.16-0.28] vs 0.07 [IQR, 0.07-0.08]; P < .001). In muscles of participants with BMD with normal FF, ECV was also higher than in muscles of healthy controls (median, 0.11 [IQR, 0.10-0.15] vs 0.07 [IQR, 0.07-0.08]; P = .02). ECV was correlated with FF (ρ = 0.56, P = .003), Walton and Gardner-Medwin scale score (ρ = 0.52, P = .006), and serum cardiac troponin T level (ρ = 0.60, P < .001). Conclusion Quantitative MR relaxometry with water and fat separation indicates a significant increase of skeletal muscle extracellular volume fraction in study participants with Becker muscular dystrophy. Clinical trial registration no. NCT02020954 Published under a CC BY 4.0 license. Supplemental material is available for this article.


  • Open Access

    Charcot-Marie-Tooth disease type 2CC due toNEFHvariants causes a progressive, non-length-dependent, motor-predominant phenotype

    by Menelaos Pipis, Andrea Cortese, James M Polke, Roy Poh, Jana Vandrovcova, Matilde Laura, Mariola Skorupinska, Arnaud Jacquier, Raul Juntas-Morales, Philippe Latour, et al.

    Objective: Neurofilaments are the major scaffolding proteins for the neuronal cytoskeleton, and variants inNEFHhave recently been described to cause axonal Charcot-Marie-Tooth disease type 2CC (CMT2CC).Methods: In this large observational study, we present phenotype–genotype correlations on 30 affected and 3 asymptomatic mutation carriers from eight families.Results: The majority of patients presented in adulthood with motor-predominant and lower limb-predominant symptoms and the average age of onset was 31.0±15.1 years. A prominent feature was the development of proximal weakness early in the course of the disease. The disease progressed rapidly, unlike other Charcot-Marie-Tooth disease (CMT) subtypes, and half of the patients (53%) needed to use a wheelchair on average 24.1 years after symptom onset. Furthermore, 40% of patients had evidence of early ankle plantarflexion weakness, a feature which is observed in only a handful of CMT subtypes. Neurophysiological studies and MRI of the lower limbs confirmed the presence of a non-length-dependent neuropathy in the majority of patients.All families harboured heterozygous frameshift variants in the last exon ofNEFH, resulting in a reading frameshift to an alternate open reading frame and the translation of approximately 42 additional amino acids from the 3' untranslated region (3′-UTR).Conclusions: This phenotype–genotype study highlights the unusual phenotype of CMT2CC, which is more akin to spinal muscular atrophy rather than classic CMT. Furthermore, the study will enable more informative discussions on the natural history of the disease and will aid inNEFHvariant interpretation in the context of the disease’s unique molecular genetics.


  • Water-Fat Separation in MR Fingerprinting for Quantitative Monitoring of the Skeletal Muscle in Neuromuscular Disorders

    by Benjamin Marty, Harmen Reyngoudt, Jean-Marc Boisserie, Julien Le Louër, Ericky C. A. Araujo, Yves Fromes, Pierre G. Carlier

    Water-fat separation in MR fingerprinting can be used to provide markers of intramuscular fatty replacement and disease activity in neuromuscular disorders. Background Quantitative MRI is increasingly proposed in clinical trials related to neuromuscular disorders (NMDs). Purpose To investigate the potential of an MR fingerprinting sequence for water an...


  • MIECT: How did it start?

    by Yves Fromes, Olivier M. Bical

    Transiently assuming the functions of both heart and lungs as surgeons repair critical valves and vessel lesions can be achieved by mechanical circulatory support has its origins in cardiopulmonary bypass (CPB). However, CPB technologies induce also some unintended adverse effects. During the 90s, a mayor trend pushed many physicians to reconsider the place of coronary artery bypass grafting (CABG) and challenged the surgical reference treatment by less invasive catheter-based angioplasties. Nevertheless, best long-term patient outcomes were related to surgery. Therefore, a small number of multidisciplinary teams in Regensburg and Paris started to develop a minimally invasive CPB system. The basic concept relied on a closed-loop perfusion circuit with a non-occlusive pump. Moreover, the team in Paris pushed the concept further and developed a complete fully integrated CPB system allowed first closed-heart and later open-heart surgery with aortic cross-clamping and efficient cardioprotection. Those were the initial steps towards the future developments of minimally invasive extracorporeal circulation technologies. Initial clinical results were clearly positive in terms of overall morbimortality. Moreover, several preliminary results pointed out the biological benefits that decreased hemodilution, improved preservation of the immune reactions and more stable anticoagulation could bring to the field of ECT.


  • Open Access

    Gene Therapy for Cardiomyopathies

    by Yves Fromes, Caroline Roques

    Heart disease remains the prevalent cause of premature death and accounts for a significant proportion of all hospital admissions. Molecular genetics was integrated quite late in cardiology, but introduced new concepts like sarcolemmopathies, cytoskeletalopathies, and channelopathies useful to better understand the pathophysiology of the development of inherited cardiomyopathies (CMs). As our understanding of the cellular and molecular processes involved in the development and progression of heart disease improved, new therapeutic targets were identified, as were novel approaches such as delivery of genes to replace defective or deficient components and thereby restore structure or function in a diseased heart. We discuss gene addition strategies in the context of monogenic disorders. Moreover, a broader nucleic acid-based modulation of cardiac gene expression for the treatment of cardiac diseases might have larger clinical indications. Inadequate gene delivery remains a potential cause of negative trials. However, progress in innovative formulations and clinically relevant ways of administration should lead to significant progress in the future. Cardiac gene therapy will be integrated into the therapeutic armamentarium for CM and heart failure.